Ahlgren GM - Search Results

1

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12. Ahlgren GM, et al. Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1. Eur Urol. 2018. PMID: 29395502 Clinical Trial.

2

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.

Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K. Hugosson J, et al. Eur Urol. 1996;29(4):413-9. doi: 10.1159/000473789. Eur Urol. 1996. PMID: 8791047 Clinical Trial.

3

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.

Ahlgren G, Lindholm K, Falkmer U, Abrahamsson PA. Ahlgren G, et al. Urology. 1997 Sep;50(3):379-84. doi: 10.1016/S0090-4295(97)00223-9. Urology. 1997. PMID: 9301701

4

Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination.

Aus G, Ahlgren G, Hugosson J, Pedersen KV, Rensfeldt K, Söderberg R. Aus G, et al. Scand J Urol Nephrol. 1997 Dec;31(6):541-4. doi: 10.3109/00365599709030659. Scand J Urol Nephrol. 1997. PMID: 9458512

5

Hormonal treatment before radical prostatectomy: a 3-year followup.

Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Aus G, et al. J Urol. 1998 Jun;159(6):2013-6; discussion 2016-7. doi: 10.1016/S0022-5347(01)63230-0. J Urol. 1998. PMID: 9598509 Clinical Trial.

6

Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy.

Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Ahlgren G, et al. Urology. 1999 Aug;54(2):329-34. doi: 10.1016/s0090-4295(99)00107-7. Urology. 1999. PMID: 10443734 Clinical Trial.

7

Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer.

Ahlgren G, Falkmer U, Gadaleanu V, Abrahamsson PA. Ahlgren G, et al. Eur Urol. 1999 Oct;36(4):314-9. doi: 10.1159/000020011. Eur Urol. 1999. PMID: 10473991

8

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment.

Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Ahlgren G, et al. Prostate. 2000 Mar 1;42(4):274-9. doi: 10.1002/(sici)1097-0045(20000301)42:4<274::aid-pros4>3.0.co;2-r. Prostate. 2000. PMID: 10679756 Clinical Trial.

9

Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma.

Tennvall J, Abrahamsson PA, Ahlgren G, Darte L, Flodgren P, Garkavij M, Strand SE. Tennvall J, et al. Scand J Urol Nephrol. 2000 Jun;34(3):188-93. doi: 10.1080/003655900750016571. Scand J Urol Nephrol. 2000. PMID: 10961473

10

The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.

Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. Giwercman YL, et al. Eur Urol. 2005 Oct;48(4):679-85. doi: 10.1016/j.eururo.2005.06.011. Eur Urol. 2005. PMID: 16039774

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page